Delivery of healthy babies after natalizumab use for multiple sclerosis: A report of two cases

Acta Neurologica Scandinavica

Volumn 123, Issue 6, 2011, Pages 430-433

  Hoevenaren, I A ^a,c   de Vries, L C ^b   Rijnders, R J P ^a   Lotgering, F K ^c  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Monoclonal antibodies; Multiple sclerosis; Natalizumab; Pregnancy

Indexed keywords

NATALIZUMAB;

ADULT; ARTICLE; CASE REPORT; DECISION MAKING; DELIVERY; DISEASE EXACERBATION; DRUG SAFETY; FEMALE; FOLLOW UP; GESTATION PERIOD; HUMAN; MULTIPLE SCLEROSIS; PATIENT COUNSELING; PERINATAL PERIOD; PREGNANCY OUTCOME; PRENATAL PERIOD; RELAPSE; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; APGAR SCORE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFANT, NEWBORN; INTEGRIN ALPHA4; MULTIPLE SCLEROSIS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RECURRENCE; TREATMENT OUTCOME;

EID: 79954560285     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01426.x     Document Type: Article

References (15)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17.
2. Ferrero S, Pretta S, Ragni N. Multiple sclerosis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 2004;115:3-9.
3. European Medicines Agency. Summary of product characteristics Tysabri. In: Human Medicines, EPARs for authorized medicinal products for human use [online]. Available at:
4. Davenport RJ, Munday JR. Alpha4-integrin antagonism - an effective approach for the treatment of inflammatory diseases? Drug Discov Today 2007;12:569-76.
5. Bowen JA, Hunt JS. The role of integrins in reproduction. Proc Soc Exp Biol Med 2000;223:331-43.
6. Mahadevan U, Nazareth M, Cristiano L, Kooijmans M, Hogge G. Natalizumab use during pregnancy. Am J Gastroenterol 2008;103(s449):1150.
7. Villard-Mackintosh L, Vessey MP. Oral contraceptives and reproductive factors in multiple sclerosis incidence. Contraception 1993;47:161-8.
8. Dahl J, Myhr KM, Daltveit AK, Hoff JM, Gilhus NE. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology 2005;65:1961-3.
9. Dahl J, Myhr KM, Daltveit AK, Gilhus NE. Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis. J Neurol 2008;255:623-7.
10. Chen YH, Lin HL, Lin HC. Does multiple sclerosis increase risk of adverse pregnancy outcomes? A population-based study. Mult Scler 2009;15:606-12.
11. Hellwig K, Brune N, Haghikia A et al. Reproductive counseling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand 2008;118:24-8.
12. Jauniaux E, Jurkovic D, Gulbis B, Liesnard C, Lees C, Campbell S. Materno-fetal immunoglobulin transfer and passive immunity during the first trimester of human pregnancy. Hum Reprod 1995;10:3297-300.
13. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 1996;36:248-55.
14. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
15. Wehner NG, Shopp G, Osterburg I, Fuchs A, Buse E, Clarke J. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an α4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol 2009;86:144-56.